VCO trials for COVID-19 patients’ use to be completed in November — DOST

Published September 14, 2020, 3:00 PM

by Dhel Nazario

One of the Virgin Coconut Oil (VCO) trials being conducted by the Department of Science and Technology (DOST) is nearing completion and the results are expected to be known in November.

(PIXABAY / MANILA BULLETIN)

“So far umaasa tayo na magiging mabuti naman ang outcome (So far we are hoping for a favorable outcome),” DOST Secretary Fortunato dela Peña said during the Palace press briefing on Monday.

Trials at the Sta. Rosa Community Hospital in Laguna would be completed after being tested on nine more patient volunteers who are confined and are suspected to have coronavirus disease (COVID-19).  Dela Pena is hoping that by the end of November all patients at the hospital are done with the trials. 

“Malapit na nating abutin kasi yung 56 na target na patients na isasagawa yung trial. Last weekend nandoon na tayo sa 47 so siguro madali na lang yung 9 additional patients (We are near our goal of 56 patients needed to conduct the trial and last weekend we are at 47, perhaps the additional nine patients will be easy to acquire), he said.

Dela Peña added that over 30 patients have already gone home but conclusions cannot be made yet but he mentioned that their conditions have improved.

At the Sta. Rosa Community Hospital, the methodology for the trials is that for 28 days the patients will be given VCO with their three meals. Their condition would then be monitored from day 0 as they enter or participate and up to day 14 and day 28.  

“Ang proseso kasi dyan yung mga volunteers hinahati yan sa dalawang section yung kalahati binibigyan ng VCO yung kalahati ay hindi (The process is that half of the volunteers will be given VCO while the other half will not),” Dela Pena said.

 “Lahat niyan ay i-aanalyze kapag tapos na iyong ating 56 patients…Yuon ay siguro mga isang buwan nila gagawin yung lahat ng analysis (All of that will be analyzed once the 56 patients have finished the trials…and the whole analysis is expected to last for one month),” he added.

Two weeks ago, dela Peña revealed in his weekly report that lauric acid and its derivatives, which is found in VCO has shown efficacy in the initial results of its in vitro studies.  

“Nakatanggap na kami ng report mula sa Ateneo kay Dr. Fabian Dayrit na natapos na yung testing in vitro trials for the efficacy of lauric acid and its derivatives versus SARS-CoV-2 (We have received a report from Ateneo given by Dr. Fabian Dayrit that the in vitro trials for the efficacy of lauric acid and its derivatives versus SARS-CoV-2 has finished),” he said.

The initial results of the study show that monolaurin and lauric acid exhibited a modest antiviral activity against SARS-CoV-2 virus in vitro. Dela Pena said that since these compounds are components of food and are generally recognized as safe, these experiments justify further studies on the use of VCO as supportive treatment for COVID-19. 

to be completed in November — DOST

By Dhel Nazario

One of the Virgin Coconut Oil (VCO) trials being conducted by the Department of Science and Technology (DOST) is nearing completion and the results are expected to be known in November.

“So far umaasa tayo na magiging mabuti naman ang outcome (So far we are hoping for a favorable outcome),” DOST Secretary Fortunato dela Peña said during the Palace press briefing on Monday.

Trials at the Sta. Rosa Community Hospital in Laguna would be completed after being tested on nine more patient volunteers who are confined and are suspected to have coronavirus disease (COVID-19). Dela Pena is hoping that by the end of November all patients at the hospital are done with the trials.

“Malapit na nating abutin kasi yung 56 na target na patients na isasagawa yung trial. Last weekend nandoon na tayo sa 47 so siguro madali na lang yung 9 additional patients (We are near our goal of 56 patients needed to conduct the trial and last weekend we are at 47, perhaps the additional nine patients will be easy to acquire), he said.

Dela Peña added that over 30 patients have already gone home but conclusions cannot be made yet but he mentioned that their conditions have improved.

At the Sta. Rosa Community Hospital, the methodology for the trials is that for 28 days the patients will be given VCO with their three meals. Their condition would then be monitored from day 0 as they enter or participate and up to day 14 and day 28.

“Ang proseso kasi dyan yung mga volunteers hinahati yan sa dalawang section yung kalahati binibigyan ng VCO yung kalahati ay hindi (The process is that half of the volunteers will be given VCO while the other half will not),” Dela Pena said.

“Lahat niyan ay i-aanalyze kapag tapos na iyong ating 56 patients…Yuon ay siguro mga isang buwan nila gagawin yung lahat ng analysis (All of that will be analyzed once the 56 patients have finished the trials…and the whole analysis is expected to last for one month),” he added.

Two weeks ago, dela Peña revealed in his weekly report that lauric acid and its derivatives, which is found in VCO has shown efficacy in the initial results of its in vitro studies.

“Nakatanggap na kami ng report mula sa Ateneo kay Dr. Fabian Dayrit na natapos na yung testing in vitro trials for the efficacy of lauric acid and its derivatives versus SARS-CoV-2 (We have received a report from Ateneo given by Dr. Fabian Dayrit that the in vitro trials for the efficacy of lauric acid and its derivatives versus SARS-CoV-2 has finished),” he said.

The initial results of the study show that monolaurin and lauric acid exhibited a modest antiviral activity against SARS-CoV-2 virus in vitro. Dela Pena said that since these compounds are components of food and are generally recognized as safe, these experiments justify further studies on the use of VCO as supportive treatment for COVID-19.

 
CLICK HERE TO SIGN-UP
 

YOU MAY ALSO LIKE

["national","news","news"]
[2424241,2602445,2602443,2602439,2602435,2602431,2602433]